10-K: China Foods Holdings Ltd. Reports Full Year 2023 Results Amidst Market Challenges

China Foods Holdings Ltd. reported its full year 2023 financial results, showing a decrease in revenue and an increased net loss compared to the previous year.

Summary

• China Foods Holdings Ltd. reported a net loss of $403,700 for the year ended December 31, 2023, compared to a net loss of $354,078 in 2022.
• The company's revenue decreased to $158,475 in 2023 from $354,096 in 2022, primarily due to the after-effects of COVID-19 and reduced demand in the wine market.
• The cost of revenue was $94,331 in 2023, compared to $243,034 in 2022.
• Gross profit for 2023 was $64,144, down from $111,062 in 2022.
• Total operating expenses were $468,781 in 2023, compared to $503,795 in 2022.
• The company's cash and cash equivalents decreased to $174,877 as of December 31, 2023, from $381,709 in the previous year.
• The company operates in two segments: Healthcare and Wine, with the Wine segment contributing the majority of the revenue in 2023 at $139,163.
• The Great Health Industry, in which the company operates, is estimated to reach approximately $2,153.08 billion in 2023, with an average annual compound growth rate of 12.55%.

Sentiment

Score: 3

Explanation: The document presents a negative outlook due to decreased revenue, increased net loss, and concerns about the company's financial stability and internal controls. The company's reliance on external financing and the risks associated with operating in China further contribute to the low sentiment score.

Positives

• The company's cost of revenue decreased as a percentage of net revenue from 68.64% in 2022 to 59.52% in 2023.
• The company has a strategy to expand its market share in China by collaborating with e-commerce platforms and strengthening relationships with suppliers.
• The company is focused on long-term growth in revenues, cash flow, and profit.

Negatives

• The company experienced a significant decrease in revenue and an increase in net loss year-over-year.
• The company's cash and cash equivalents decreased significantly.
• The company's operations have been impacted by the COVID-19 pandemic and sluggish demand in the wine market.
• The company has a history of net losses and expects to continue to incur net losses for the foreseeable future.

Risks

• The company faces risks and uncertainties related to doing business in China, including evolving laws and regulations.
• The company's ability to offer securities to investors could be limited by the PRC government's oversight.
• The company is subject to the Holding Foreign Companies Accountable Act (HFCAA), which could lead to delisting if the PCAOB is unable to inspect the company's auditor.
• The company's material cash requirements are highly dependent upon additional financial support from major shareholders.
• The company's internal control over financial reporting was deemed not effective as of December 31, 2023.

Future Outlook

The company expects to continue to rely on cash generated through financing from existing shareholders and private placements of securities to finance operations and future acquisitions. The company expects net cash expended in 2024 to be higher than 2023.

Management Comments

• Management believes the existing shareholders or external financing will provide additional cash to meet the Company's obligations as they become due.
• Management believes that the material weakness set forth above did not have an effect on our financial results.

Industry Context

The company operates in the Great Health Industry, which is an emerging industry with huge market potential, especially in China. The industry is predicted to reach approximately $2,153.08 billion in 2023, with an average annual compound growth rate of 12.55%. The company faces competition from larger e-commerce companies and other businesses in the health and wellness sector.

Comparison to Industry Standards

• The company's performance is below industry standards, as evidenced by the decrease in revenue and increase in net loss.
• Competitors such as UNI HEALTH (HK stock code: 02211) and ALI HEALTH (HK stock code:0241) are likely to have stronger financial performance and market presence.
• The company's reliance on external financing and its lack of profitability are not in line with industry leaders.
• The company's internal control weaknesses are a concern compared to industry best practices.

Related Party Transactions

• The company has related party transactions with its director and a related company, involving temporary advances for working capital purposes.

Stakeholder Impact

• Shareholders are negatively impacted by the company's poor financial performance and increased net loss.
• Employees may be concerned about the company's financial stability and future prospects.
• Customers may experience delays in receiving products due to the impact of COVID-19.
• Suppliers may face uncertainty due to the company's financial challenges.

Next Steps

• The company plans to collaborate with third-party e-commerce platforms to boost product exposure.
• The company intends to deliver healthcare knowledge and consultation services via social media.
• The company aims to build brand image and reputation through customer experience.
• The company plans to increase the number of downstream distributors and wholesalers.
• The company intends to strengthen relationships with manufacturers, suppliers, and distributors.
• The company plans to pursue strategic acquisitions and partnerships.

Key Dates

Keywords

healthcare, wine, China, financial results, revenue, net loss, COVID-19, e-commerce, supply chain, HFCAA, PCAOB